Top Story Today
The Venture-Backed Biotech IPO That Just Broke Every Record
Parabilis Medicines raised $670 million in the largest venture-backed biotech IPO in history, then watched its stock pop 58% on day one. The kicker: the company inked a $2.3 billion Regeneron collaboration the day before going public, pulling in roughly $745 million in a single week. Parabilis builds tiny corkscrew-shaped peptides called Helicons that can slip inside cells and grab proteins traditional drugs can't reach. The deal dethroned Kailera Therapeutics, which held the record for all of two months.
Why it matters: This record-shattering debut doesn't mean the IPO window is wide open; it means it's open for the elite. Fewer companies are raising bigger checks, and the gap between biotech haves and have-nots has never been wider.
Read more →The Obesity and Autoimmune Wars
Takeda's Psoriasis Pill Just Doubled Sotyktu's Best Numbers
Takeda's zasocitinib delivered 35% complete skin clearance at 16 weeks in a head-to-head trial against BMS's Sotyktu, more than doubling the rival drug's rate. It won on every key endpoint. Takeda paid $4 billion for this drug back in 2022 after it posted positive Phase 2b results; that bet is looking very smart now.
Read more →Novo's Chief Scientist Concedes the Obesity Crown Is Up for Grabs
Novo Nordisk's CSO publicly admitted CagriSema's weight loss numbers aren't competitive with Lilly's retatrutide, which posted 28.3% average weight loss versus CagriSema's 22.7%. With Novo's stock already down 35% over the past year, this rare concession from the incumbent signals the obesity throne is genuinely contested.
Read more →AstraZeneca Cannonballs Into the Obesity Pill Race
AstraZeneca committed to a massive Phase 3 program for its oral GLP-1 pill, elecoglipron, after Phase 2 data showed nearly 12% weight loss at 36 weeks. The numbers are solid, not spectacular, but AstraZeneca's real edge may be manufacturing: as a small molecule (not a peptide), elecoglipron is cheaper to produce and simpler to take.
Read more →Sanofi Halts Another Trial as the Dupixent Clock Ticks Louder
Sanofi pulled the plug on its Phase 3 riliprubart trial in CIDP after an interim review concluded the drug was unlikely to work. It's the latest in a string of setbacks: its top Dupixent successor underwhelmed, its MS drug failed, and core patents start expiring around 2031. Wall Street is running out of patience.
Read more →Oncology and Cell Therapy
A Tiny Biotech Just Put Novartis's Leukemia Empire on Notice
Enliven Therapeutics posted Phase 1b data showing 47% of heavily pretreated CML patients hit major molecular response at 24 weeks, with zero cardiovascular toxicity signals. Almost every analyst covering the company rates it a Buy, with price targets as high as $80. A pivotal Phase 3 trial is planned for late 2026.
Read more →Caribou's Frozen CAR-T Cells Are Catching Up to Custom-Made Therapy
Caribou's off-the-shelf CAR-T cells hit 82% response rates in lymphoma and 92% in myeloma, with zero cases of graft-versus-host disease across its clinical programs. If frozen donor cells can truly rival $400,000 personalized treatments (at a fraction of the manufacturing cost), the economics of cancer therapy could fundamentally shift.
Read more →Science and Startups
This Startup Wants to Deliver Gene Therapy With Sound Waves
SonoThera raised $125 million to deliver genetic medicines using ultrasound and microbubbles instead of viruses. Multiple pharma venture arms wrote checks. The approach could deliver full-length genes that are too large for traditional viral vectors, with first-in-human trials planned for 2027. It's still preclinical, but the investor lineup says the industry is taking it seriously.
Read more →A $101M Startup Wants to Attack Thyroid Eye Disease at Its Root
Ethyreal Bio launched with $101 million and a plan to block the TSH receptor, the upstream trigger of thyroid eye disease, rather than mopping up downstream like Amgen's $1.9 billion blockbuster Tepezza. The drug is designed as a self-injectable, and a first-in-human trial is planned for later this year.
Read more →Your Ozempic Might Be Growing a Tiny Therapist in Your Gut
A new study in Cell Host & Microbe found that GLP-1 drugs promote growth of a gut bacterium called Lactobacillus delbrueckii, which produces a molecule that calms stress circuits in the brain. When researchers wiped out gut bacteria first, the antidepressant effect vanished entirely. It's a mouse study for now, but the implications for a $70 billion drug class are enormous.
Read more →